- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Blue Jet Healthcare posted FY'25 revenue of Rs. 1,030 Cr (+45% YoY), EBITDA of Rs. 378 Cr with a 37% margin (+65%), and PAT of Rs. 305 Cr (+87%). Q4 revenue rose 7% QoQ and 85% YoY, with EBITDA margin at 41%. Pharma intermediates/API soared 4x YoY, led by cardiovascular products; contrast media stabilized, supported by new launches. Unit-2 CDMO operates at 60-65% capacity, while Unit-3 advances on continuous processing and GMP facilities targeting FY’27. A new Rs. 40 Cr R&D center focuses on amino acid derivatives and NCEs. Management cites multi-year contracts, China supply shifts, zero debt, and Rs. 285 Cr cash. Analyst questions covered growth drivers, capacity, and product ramps. The outlook remains confident with structural tailwinds and strong client demand.